ID: ALA4292800

Max Phase: Preclinical

Molecular Formula: C21H27N5O8

Molecular Weight: 477.47

Molecule Type: Small molecule

Representations

Canonical SMILES:  CN(C)c1ccc(-c2cn(CC(=O)N[C@H]3[C@H]([C@H](O)[C@H](O)CO)OC(C(=O)O)=C[C@@H]3O)nn2)cc1

Standard InChI:  InChI=1S/C21H27N5O8/c1-25(2)12-5-3-11(4-6-12)13-8-26(24-23-13)9-17(30)22-18-14(28)7-16(21(32)33)34-20(18)19(31)15(29)10-27/h3-8,14-15,18-20,27-29,31H,9-10H2,1-2H3,(H,22,30)(H,32,33)/t14-,15+,18+,19+,20+/m0/s1

Standard InChI Key:  KFFPNNIJIGOPQI-MZCHELMPSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 477.47

Molecular Weight (Monoisotopic): 477.1860

AlogP: -2.06

#Rotatable Bonds: 9

Polar Surface Area: 190.50

Molecular Species: ACID

HBA: 11

HBD: 6

#RO5 Violations: 2

HBA (Lipinski): 13

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 3.07

CX Basic pKa: 3.95

CX LogP: -3.02

CX LogD: -5.29

Aromatic Rings: 2

Heavy Atoms: 34

QED Weighted: 0.23

Np Likeness Score: -0.28

References

1. Guo T, Héon-Roberts R, Zou C, Zheng R, Pshezhetsky AV, Cairo CW..  (2018)  Selective Inhibitors of Human Neuraminidase 1 (NEU1).,  61  (24): [PMID:30457869] [10.1021/acs.jmedchem.8b01411]

2.  (2018)  Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase, 

Source

Source(2):

• Scientific Literature
• Patent Bioactivity Data